West Pharmaceutical Services Cash Flow from Operating Activities 2012-2026 | WST
West Pharmaceutical Services annual/quarterly cash flow from operating activities history and growth rate from 2012 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
- West Pharmaceutical Services cash flow from operating activities for the quarter ending March 31, 2026 was $0.504B, a 8.72% increase year-over-year.
- West Pharmaceutical Services cash flow from operating activities for the twelve months ending March 31, 2026 was $1.593B, a 2.94% decline year-over-year.
- West Pharmaceutical Services annual cash flow from operating activities for 2024 was $0.653B, a 15.85% decline from 2023.
- West Pharmaceutical Services annual cash flow from operating activities for 2023 was $0.777B, a 7.25% increase from 2022.
- West Pharmaceutical Services annual cash flow from operating activities for 2022 was $0.724B, a 23.97% increase from 2021.
|
West Pharmaceutical Services Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2024 | $653 |
| 2023 | $777 |
| 2022 | $724 |
| 2021 | $584 |
| 2020 | $473 |
| 2019 | $367 |
| 2018 | $289 |
| 2017 | $263 |
| 2016 | $219 |
| 2015 | $212 |
| 2014 | $183 |
| 2013 | $221 |
| 2012 | $187 |
| 2011 | $131 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $18.493B | $3.074B |
| West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments: Proprietary Products and Contract-Manufactured Products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| Becton Dickinson (BDX) | United States | $43.913B | 11.10 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |